Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 10월 2023 - 5:27AM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancer, today announced that on October 2,
2023, the Compensation Committee of Zentalis’ Board of Directors
granted non-qualified stock options to purchase an aggregate of
101,375 shares of the Company’s common stock to four newly hired
employees. The stock options were granted under the Zentalis
Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award
Plan (2022 Inducement Plan) as an inducement material to each
individual’s entering into employment with Zentalis in accordance
with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
Zentalis, or following a bona fide period of non-employment, as an
inducement material to such individuals’ entering into employment
with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $19.86 per share,
which is equal to the closing price of Zentalis’ common stock on
The Nasdaq Global Market on the date of grant. The stock options
have a 10-year term and will vest over four years, with 25% of the
options vesting on the first anniversary of the vesting
commencement date and the remaining 75% of the options vesting in
equal monthly installments over the three years thereafter. Vesting
of the stock options is subject to each employee’s continued
service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company discovering and developing small molecule
therapeutics targeting fundamental biological pathways of cancers.
Utilizing its Integrated Discovery Engine, the Company is
developing a focused pipeline of potentially best-in-class oncology
candidates, which include azenosertib (ZN-c3), a WEE1 inhibitor for
advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic
malignancies and related disorders, and a heterobifunctional
degrader of BCL-xL for solid and hematological malignancies. The
Company is also leveraging its extensive experience and
capabilities across cancer biology and medicinal chemistry to
advance its research on protein degraders. Zentalis has operations
in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:
Katie Beach Oltsik Evoke
CanaleKatherine.Beach@evokegroup.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024